Our Pipeline
We develop a broad portfolio of small molecule RNA-modifying drug candidates that have the potential to improve the lives of patients by directly addressing the causes of disease. Skyhawk’s portfolio includes both internal and partnered programs across neurodegenerative, oncology, neuromuscular, rare and other disease types. Many of our programs are against targets formerly considered “undruggable” for traditional protein-targeting mechanisms.
THERAPEUTIC AREA
Autoimmune Target
Discovery
Preclinical
IND-Enabling
Clinical
Autoimmune Target
Discovery
Preclinical
IND-Enabling
Clinical
Cancer Target
Discovery
Preclinical
IND-Enabling
Clinical
Cancer Target
Discovery
Preclinical
IND-Enabling
Clinical
Cancer Target
Discovery
Preclinical
IND-Enabling
Clinical
Cancer Target
Discovery
Preclinical
IND-Enabling
Clinical
Cancer Target
Discovery
Preclinical
IND-Enabling
Clinical
Cancer Target
Discovery
Preclinical
IND-Enabling
Clinical
Muscular Target
Discovery
Preclinical
IND-Enabling
Clinical
Neurodegenerative Target
Discovery
Preclinical
IND-Enabling
Clinical
Neurodegenerative Target
Discovery
Preclinical
IND-Enabling
Clinical
Neurodegenerative Target
Discovery
Preclinical
IND-Enabling
Clinical
Neurodegenerative Target
Discovery
Preclinical
IND-Enabling
Clinical
Neurodegenerative Target
Discovery
Preclinical
IND-Enabling
Clinical
Neuromuscular Target
Discovery
Preclinical
IND-Enabling
Clinical
Neuromuscular Target
Discovery
Preclinical
IND-Enabling
Clinical
Neuromuscular Target
Discovery
Preclinical
IND-Enabling
Clinical